Pharmacokinetics and in vitro effects of tegaserod, a serotonin 5-hydroxytryptamine 4 (5-HT4) receptor agonist with prokinetic activity in horses

Michele L. Delco, Jorge Nieto, Athur L. Craigmill, Scott D Stanley, Jack R. Snyder

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Tegaserod, a serotonin agonist, has been shown to have prokinetic effects in horses, but pharmacokinetic information is not currently available. The pharmacokinetics and in vitro effects of tegaserod were evaluated. Tegaserod increased the contractile activity of smooth muscle preparations of the equine pelvic flexure. Pertinent pharmacokinetic parameters for a single IV and oral dose were determined. Therapeutic plasma concentrations of tegaserod were achieved with a single oral dose at 0.27 mg/kg. These findings indicate that further clinical studies are warranted to investigate potential benefits in cases of functional gastrointestinal motility disorders in horses.

Original languageEnglish (US)
Pages (from-to)77-87
Number of pages11
JournalVeterinary Therapeutics
Volume8
Issue number1
StatePublished - Mar 2007

Fingerprint

Receptors, Serotonin, 5-HT4
serotonin
agonists
pharmacokinetics
Horses
Serotonin
Pharmacokinetics
horses
receptors
mouth
gastrointestinal motility
dosage
Serotonin Receptor Agonists
smooth muscle
Gastrointestinal Motility
Gastrointestinal Diseases
clinical trials
Smooth Muscle
therapeutics
tegaserod

ASJC Scopus subject areas

  • veterinary(all)
  • Animal Science and Zoology

Cite this

Pharmacokinetics and in vitro effects of tegaserod, a serotonin 5-hydroxytryptamine 4 (5-HT4) receptor agonist with prokinetic activity in horses. / Delco, Michele L.; Nieto, Jorge; Craigmill, Athur L.; Stanley, Scott D; Snyder, Jack R.

In: Veterinary Therapeutics, Vol. 8, No. 1, 03.2007, p. 77-87.

Research output: Contribution to journalArticle

@article{83f4571558ea46e4b6c04731a4839f2c,
title = "Pharmacokinetics and in vitro effects of tegaserod, a serotonin 5-hydroxytryptamine 4 (5-HT4) receptor agonist with prokinetic activity in horses",
abstract = "Tegaserod, a serotonin agonist, has been shown to have prokinetic effects in horses, but pharmacokinetic information is not currently available. The pharmacokinetics and in vitro effects of tegaserod were evaluated. Tegaserod increased the contractile activity of smooth muscle preparations of the equine pelvic flexure. Pertinent pharmacokinetic parameters for a single IV and oral dose were determined. Therapeutic plasma concentrations of tegaserod were achieved with a single oral dose at 0.27 mg/kg. These findings indicate that further clinical studies are warranted to investigate potential benefits in cases of functional gastrointestinal motility disorders in horses.",
author = "Delco, {Michele L.} and Jorge Nieto and Craigmill, {Athur L.} and Stanley, {Scott D} and Snyder, {Jack R.}",
year = "2007",
month = "3",
language = "English (US)",
volume = "8",
pages = "77--87",
journal = "Veterinary therapeutics : research in applied veterinary medicine",
issn = "1528-3593",
publisher = "Veterinary Learning Systems",
number = "1",

}

TY - JOUR

T1 - Pharmacokinetics and in vitro effects of tegaserod, a serotonin 5-hydroxytryptamine 4 (5-HT4) receptor agonist with prokinetic activity in horses

AU - Delco, Michele L.

AU - Nieto, Jorge

AU - Craigmill, Athur L.

AU - Stanley, Scott D

AU - Snyder, Jack R.

PY - 2007/3

Y1 - 2007/3

N2 - Tegaserod, a serotonin agonist, has been shown to have prokinetic effects in horses, but pharmacokinetic information is not currently available. The pharmacokinetics and in vitro effects of tegaserod were evaluated. Tegaserod increased the contractile activity of smooth muscle preparations of the equine pelvic flexure. Pertinent pharmacokinetic parameters for a single IV and oral dose were determined. Therapeutic plasma concentrations of tegaserod were achieved with a single oral dose at 0.27 mg/kg. These findings indicate that further clinical studies are warranted to investigate potential benefits in cases of functional gastrointestinal motility disorders in horses.

AB - Tegaserod, a serotonin agonist, has been shown to have prokinetic effects in horses, but pharmacokinetic information is not currently available. The pharmacokinetics and in vitro effects of tegaserod were evaluated. Tegaserod increased the contractile activity of smooth muscle preparations of the equine pelvic flexure. Pertinent pharmacokinetic parameters for a single IV and oral dose were determined. Therapeutic plasma concentrations of tegaserod were achieved with a single oral dose at 0.27 mg/kg. These findings indicate that further clinical studies are warranted to investigate potential benefits in cases of functional gastrointestinal motility disorders in horses.

UR - http://www.scopus.com/inward/record.url?scp=34249703501&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34249703501&partnerID=8YFLogxK

M3 - Article

VL - 8

SP - 77

EP - 87

JO - Veterinary therapeutics : research in applied veterinary medicine

JF - Veterinary therapeutics : research in applied veterinary medicine

SN - 1528-3593

IS - 1

ER -